{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:55:59Z","timestamp":1790394959042,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.nucmedbio.2013.01.007","type":"journal-article","created":{"date-parts":[[2013,2,27]],"date-time":"2013-02-27T19:21:20Z","timestamp":1361992880000},"page":"451-457","source":"Crossref","is-referenced-by-count":57,"title":["Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas"],"prefix":"10.1016","volume":"40","author":[{"given":"Sibaprasad","family":"Bhattacharyya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kurdziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Riffle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurmeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Craig","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Tatum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Kalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0005","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.mibio.2004.04.003","article-title":"Positron emission tomography as a tool for translational research in oncology","volume":"6","author":"Stahl","year":"2004","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0010","series-title":"Handbook of radiopharmaceuticals, radiochemistry and applications","author":"Welch","year":"2003"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0015","first-page":"561","article-title":"Clinical PET: it's time has come","volume":"32","author":"Wagner","year":"1991","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0020","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1039\/c1dt10379b","article-title":"Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals","volume":"50","author":"Bhattacharyya","year":"2011","journal-title":"Dalton Trans"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2967\/jnumed.108.056887","article-title":"Antibodies and antimatter: the resurgence of immuno-PET","volume":"50","author":"Wu","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0030","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1021\/bc800299f","article-title":"Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges","volume":"20","author":"Nayak","year":"2009","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/PPO.0b013e31817b07ae","article-title":"Antibodies for molecular imaging of cancer","volume":"14","author":"Wu","year":"2008","journal-title":"Cancer J"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/08977190802312844","article-title":"EGFR family: structure physiology signaling and therapeutic targets","volume":"26","author":"Burgess","year":"2008","journal-title":"Growth Factors"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0045","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1517\/13543784.11.6.755","article-title":"Anti-epidermal growth factor receptor drugs in cancer therapy","volume":"11","author":"Ciardiello","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0050","article-title":"Development of 89Zr-labeled panitumumab as EGFR-targeted PET imaging agent","author":"Bhattacharyya","year":"2011"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0055","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2967\/jnumed.109.071290","article-title":"Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma","volume":"51","author":"Nayak","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0060","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clinthera.2008.01.014","article-title":"Panitumumab: human monoclonal antibody against the epidermal growth factor receptors for the treatment of metastatic colorectal cancer","volume":"30","author":"Wu","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1040-8428(00)00134-7","article-title":"Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy","volume":"38","author":"Yang","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0070","first-page":"1271","article-title":"89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies","volume":"44","author":"Verel","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0075","doi-asserted-by":"crossref","unstructured":"Holland, J. P., Caldas-Lopes, E., Divilov, V., Longo, V. A., Taldone, T., Zatorska, D., Chiosis, G., and Lewis, J. S. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2\/neu expression in mice using 89Zr-DFO-trastuzumab. PloS ONE 2010, 5: e8859, 1-11.","DOI":"10.1371\/journal.pone.0008859"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0080","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00259-009-1263-1","article-title":"p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno- imaging","volume":"37","author":"Perk","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"33","key":"10.1016\/j.nucmedbio.2013.01.007_bb0085","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00259-006-0160-0","article-title":"Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography","volume":"2006","author":"Perk","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0090","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1158\/1078-0432.CCR-05-2137","article-title":"Performance of immuno positron emission tomography with zirconium-89 labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients","volume":"12","author":"B\u00f6rjesson","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.nucmedbio.2013.01.007_bb0095","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2967\/jnumed.111.094169","article-title":"PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab","volume":"53","author":"Nayak","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0100","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.nucmedbio.2009.05.007","article-title":"Standardized method for the production of high specific activity zirconium-89","volume":"36","author":"Holland","year":"2009","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0105","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1476-5381.2009.00327.x","article-title":"Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent","volume":"157","author":"Ray","year":"2009","journal-title":"Br J Pharm"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0110","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.2967\/jnumed.107.050203","article-title":"Routine quality control of clinical nuclear medicine instrumentation: a brief review","volume":"49","author":"Zanzonico","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/0003-2697(84)90517-7","article-title":"Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions","volume":"142","author":"Meares","year":"1984","journal-title":"Anal Biochem"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0125","unstructured":"Bhattacharyya, S., Cheal, S. M., Hill, G. C., and Griffiths, G.L. Radiometric metal binding assay to determine chelate to protein ratio: a comparative study between 57Co and 111In. Am. Chem. Soc. Meeting, 2009, Washington DC (abstract)."},{"issue":"3","key":"10.1016\/j.nucmedbio.2013.01.007_bb0130","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-05-1182","article-title":"Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells","volume":"66","author":"Konecny","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0135","unstructured":"Stabin MG, Fundamentals of nuclear medicine dosimetry, Springer, 2008."},{"key":"10.1016\/j.nucmedbio.2013.01.007_bb0140","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.nucmedbio.2013.01.007_bb0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/CAD.0b013e32800feecb","article-title":"Panitumumab the first fully human monoclonal antibody: from the bench to the clinic","volume":"18","author":"Cohenuram","year":"2007","journal-title":"Anticancer Drugs"},{"issue":"15","key":"10.1016\/j.nucmedbio.2013.01.007_bb0150","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2004.11.061","article-title":"Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer","volume":"22","author":"Rowinsky","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.nucmedbio.2013.01.007_bb0155","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.ijrobp.2003.09.098","article-title":"Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody","volume":"58","author":"Foon","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805113000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805113000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T16:36:37Z","timestamp":1644424597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805113000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0969805113000103"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2013.01.007","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}